Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
Retreatment of Chronic Hepatitis C Non-responders With Pegylated Interferon Alpha Plus Ribavirin Plus Pioglitazone
- Conditions
- Interventions
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- University Hospital, Geneva
- Target Recruit Count
- 5
- Registration Number
- NCT00433069
- Locations
- 🇨🇭
Service de Gastroentérologie et d'Hépatologie, University Hospital, Geneva, GE, Switzerland
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2013-04-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 803
- Registration Number
- NCT00432276
Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2016-11-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 67
- Registration Number
- NCT00427999
- Locations
- 🇩🇪
Novartis Investigative Site, Tübingen, Germany
Ketosis Prone Diabetes in African-Americans
- Conditions
- Interventions
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Emory University
- Target Recruit Count
- 44
- Registration Number
- NCT00426413
- Locations
- 🇺🇸
Grady Memorial Hospital, Atlanta, Georgia, United States
Effect of Pioglitazone on Cardiovascular Outcome on Higashi-Saitama Trial in Patients With Type 2 Diabetes
- Conditions
- First Posted Date
- 2007-01-08
- Last Posted Date
- 2007-01-08
- Lead Sponsor
- Dokkyo Medical University
- Target Recruit Count
- 1000
- Registration Number
- NCT00419484
- Locations
- 🇯🇵
Dokkyo Medical University, Koshigaya Hospital, Koshigaya, Saitama, Japan
Effect of Inhaled Insulin (AERx® iDMS) on Blood Glucose Control in Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2006-12-15
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 196
- Registration Number
- NCT00411892
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Tacoma, Washington, United States
Effects of Pioglitazone Treatment on Sympathetic Nervous System Function in Metabolic Syndrome Obesity
- First Posted Date
- 2006-12-07
- Last Posted Date
- 2013-01-17
- Lead Sponsor
- Baker Heart Research Institute
- Target Recruit Count
- 44
- Registration Number
- NCT00408850
- Locations
- 🇦🇺
Baker Heart Research Institute, Melbourne, Victoria, Australia
"TAKE TIME" Pioglitazone Reverses Defects in Mitochondrial Biogenesis in Patients With T2DM
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2015-12-18
- Lead Sponsor
- Pennington Biomedical Research Center
- Target Recruit Count
- 24
- Registration Number
- NCT00402012
- Locations
- 🇺🇸
Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States
Efficacy and Safety of Acitretin Plus Pioglitazone in Patients With Psoriasis
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2019-03-20
- Target Recruit Count
- 40
- Registration Number
- NCT00395941
- Locations
- 🇮🇳
PGIMER, Chandigarh, India
Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2013-03-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 655
- Registration Number
- NCT00395512
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.